Akeso Pharmaceuticals, a subsidiary of Akesobio, and Guangzhou High-tech Investment Group held a strategic cooperation signing ceremony on Nov 15. The group will provide 500 million yuan ($70 million) of financial support to the joint venture.
Akeso Pharmaceuticals is a key enterprise in Guangzhou, mainly responsible for the clinical development, industrialization, and commercialization of Cadonilimab, a new antibody drug that was independently developed by Akesobio.
Approved for marketing in June 2022, Cadonilimab is the world's first dual immune checkpoint bispecific antibody that deals with a range of tumors, and the first independently developed bispecific antibody medicine approved in China.
Akesobio's R&D and production base are located in China-Singapore Guangzhou Knowledge City (CSGKC).
All materials marked with "source: English.gz.gov.cn" on this website (including but not limited to text, photographs, audio and video materials) are the copyrighted property of Guangzhou International (the official website of Guangzhou Municipality). Without prior authorization from Guangzhou International, any media, website, organization or individual shall not transmit, interlink, distribute or republish such materials in any form. Any media and website authorized to republish such materials shall mark them with "source: Guangzhou International (English.gz.gov.cn)". Infringement of these copyrights will result in legal action.